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Cancer stem cells (CSCs) can drive tumor growth,
and their maintenance may rely on post-transcrip-
tional regulation of gene expression, including that
mediated by microRNAs (miRNAs). The let-7 miRNA
family has been shown to induce differentiation by
silencing stem cell programs. Let-7-mediated target
gene suppression is prevented by LIN28A/B, which
reduce let-7 biogenesis in normal embryonic and
some cancer stem cells and ensure maintenance
of stemness. Here, we find that glioblastoma stem
cells (GSCs) lack LIN28 and express both let-7 and
their target genes, suggesting LIN28-independent
protection from let-7 silencing. Using photoac-
tivatable-ribonucleoside-enhanced crosslinking and
immunoprecipitation (PAR-CLIP), we show that insu-
lin-like growth factor 2 mRNA-binding protein 2
(IMP2) binds to let-7 miRNA recognition elements
(MREs) and prevents let-7 target gene silencing.
Our observations define the RNA-binding repertoire
of IMP2 and identify a mechanism whereby it sup-
ports GSC and neural stem cell specification.SIGNIFICANCE
Human tumors are shaped by genetic evolution of cancer cells
but also display superimposed hierarchies reminiscent of tissue
development, where cancer stem cells (CSCs) can drive tumor
growth and give rise to differentiated progeny. The mechanisms
that underlie CSC emergence and ensure their maintenance are1634 Cell Reports 15, 1634–1647, May 24, 2016 ª 2016 The Author(s
This is an open access article under the CC BY license (http://creativediverse, rendering their understanding key for designing thera-
peutic strategies aimed toward eliminating CSC properties or
the cells themselves. We show that the RNA-binding protein
IMP2 helps maintain glioblastoma stem cells by blocking the
target gene silencing action of let-7 miRNA family members,
which play a central role in abolishing stemness and promoting
differentiation. Our observations elucidate a novel mechanism
implicated in let-7 target gene protection and GSC maintenance
that may be amenable to therapeutic targeting.INTRODUCTION
Glioblastoma (GBM) is themost common and themost lethal pri-
mary brainmalignancy in adults, with a 5-year survival rate below
5%, despite aggressive multimodal therapy. Refractoriness to
therapy is believed to reside in high intra-tumor heterogeneity re-
sulting in part from hierarchical tumor cell organization (Patel
et al., 2014). Glioblastoma contains highly plastic subpopula-
tions of cells that are capable of self-renewal, tumor initiation,
and differentiation into cells that constitute the tumor bulk,
consistent with the functional definition of cancer stem cells
(CSCs) (Kreso and Dick, 2014). These cells are commonly
referred to as glioma stem cells (GSCs) and are thought to
bear the principal responsibility for resistance to therapy and
relapse (Singh et al., 2003; Chen et al., 2012; Bao et al., 2006).
GSCplasticity is a product of epigenetic and post-transcriptional
programs that determine cell hierarchies during normal devel-
opment and neoplastic growth. Epigenetic modifications of
DNA and chromatin, as well as post-transcriptional regulation
of gene expression by non-coding RNAs, including microRNAs
(miRNAs), underlie reprogramming of non-cancerous cells
during development and tissue repair. The same mechanisms
are believed to be responsible for the reprogramming that)
commons.org/licenses/by/4.0/).
accompanies transformation and drives CSC development.
Although the complexity of epigenetic and post-transcriptional
regulation of the genome precludes prediction as to which
particular programs dominate CSC specification in different can-
cer types, the ability of miRNAs to fine-tune expression of entire
gene networks places themamong prime candidate contributors
toward establishing and maintaining CSC properties.
miRNAs and RNA-binding proteins (RBPs) are expressed in
a cell-type- and state-dependent fashion and constitute two
essential regulators of mRNA stability. miRNAs are 21- to 22-nt
non-coding RNAs that mediate post-transcriptional silencing
by target mRNA degradation or translational repression (Bartel,
2009) and that are implicated in the regulation of virtually all bio-
logical processes in multicellular organisms (He and Hannon,
2004; Yu et al., 2007). Following transcription by RNA polymer-
ase II, primary precursor miRNAs undergo sequential endonu-
cleolytic cleavage by RNase III enzymes Drosha and Dicer in
the nucleus and cytoplasm, respectively, to yield 21- to 22-nt
double-stranded RNA (Lee et al., 2002). The duplex is then
loaded onto the RNA-induced silencing complex (RISC), the
core of which consists of Argonaute proteins (AGO1-4), and
the passenger strand is unwound and removed leaving the guide
strand to target transcripts for repression. Imperfect comple-
mentarity allows a single miRNA to target hundreds of mRNAs,
many of which may function in concert to modulate cell fate tran-
sitions (Ivey and Srivastava, 2010). Alterations in global or
selected miRNA biogenesis can therefore have a powerful
impact on normal and cancer stem cell fate, as recently demon-
strated in diverse cancer types (De Vito et al., 2012; Melo et al.,
2010; Takahashi et al., 2014).
RBPs affect critical steps of posttranscriptional gene regula-
tion, including mRNA maturation, splicing, translation, and
stability (Gerstberger et al., 2014). Recent evidence suggests
that a subset of RBPs can modulate miRNA-mediated mRNA
silencing by binding sequences at or in close proximity to miRNA
recognition elements (MREs) (reviewed in van Kouwenhove
et al., 2011). However, only a few RBPs have been assigned
oncogenic or tumor suppressive functions thus far (van Kouwen-
hove et al., 2011), and fewer still are known to play a relevant role
in CSC biology. Notable exceptions are the oncofetal RBPs
LIN28A/B (collectively referred to as LIN28), which are potent on-
cogenes expressed in embryonic stem cells andCSCs of several
tumor types (Shyh-Chang and Daley, 2013; Nguyen et al., 2014)
that selectively inhibit biogenesis of let-7, a 13-member tumor-
suppressor miRNA family (Viswanathan et al., 2008, 2009; Heo
et al., 2009). Let-7 miRNAs are highly evolutionarily conserved
heterochronic genes, which in mammals regulate differentiation
of, among others, embryonic stem cells (Viswanathan et al.,
2008). Repression of let-7 family members by LIN28 is associ-
ated with normal stem cell maintenance and may participate in
transformation as well as CSC emergence in diverse tumor types
(Viswanathan et al., 2009; Nguyen et al., 2014). In the physiolog-
ical context, the LIN28/let-7 axis operates to maintain either an
embryonic stem cell or a differentiated state and may be ex-
ploited by tumor cells to modulate their own plasticity.
In this work, we interrogated the implication of miRNAs in
primary GSC establishment and maintenance and found that
the let-7 miRNA family and many of its target genes are highlyexpressed in both GSCs and their non-tumorigenic progeny.
LIN28was not detected in primary GBMcell cultures, suggesting
that alternative, LIN28-independentmechanismsmay contribute
to preserve GSCs from let-7 tumor- and stemness-suppressive
functions. We previously showed that the oncofetal RBP insu-
lin-like growth factor 2 mRNA-binding protein 2 (IMP2), a canon-
ical let-7 target, is highly expressed in GSCs and essential for
their maintenance (Janiszewska et al., 2012). IMP2 belongs to
a family of RBPs (together with IMP1 and IMP3) that are almost
exclusively expressed during embryogenesis and involved in
RNA localization, translation, and stability (Bell et al., 2013; Niel-
sen et al., 1999). IMPs are frequently re-expressed in diverse
cancer types, where they may participate in invasion, metas-
tasis, and CSC maintenance (Sto¨hr and H€uttelmaier, 2012;
Janiszewska et al., 2012). Intriguingly, we found IMP2 to be
co-expressed with several validated let-7 targets in GBM cells
and therefore addressed the possibility that as an RBP, IMP2
may promote tumorigenicity and stemness in GBM by prevent-
ing let-7 target gene silencing.
Using photoactivatable-ribonucleoside-enhanced crosslink-
ing and immunoprecipitation (PAR-CLIP) of IMP2 to identify
RNA-RBP interactions with high resolution (Hafner et al., 2010),
in primary proneural GSCs and their progeny, we show that
IMP2 binds a subset of transcripts, including let-7 targets,
directly on predicted MREs and protects them from miRNA-
dependent silencing. Loss of clonogenicity and tumor-initiating
capacity incurred by GSCs depleted of IMP2 was rescued by
LIN28B, which restored expression of let-7 responsive tran-
scripts. Similar to its effects in GSCs, IMP2 deletion repressed
candidate let-7 target genes in sub-ventricular zone (SVZ) neural
stem cells (NSCs) and impaired NSC clonogenicity in vitro. Our
observations demonstrate that IMP2 helps specify GSC features
in part by protecting let-7 family target transcripts from degrada-
tion and uncover a LIN28-independent mechanism shared by
GSCs and NSCs that prevents let-7 target gene silencing.
RESULTS
Let-7 Family Members and Their Target mRNAs Are
Highly Expressed in Primary GBMs
To identify candidate miRNAs that may be important in GSC
specification, we assessed global miRNA levels in recently char-
acterized primary GBMcells derived from three different patients
(Wakimoto et al., 2012; Rheinbay et al., 2013; Suva` et al., 2014).
GSCs can be propagated as spheroids (the terms spheroid and
sphere will henceforth be used interchangeably) under serum-
free conditions in vitro and phenocopy the parental tumor
following xenotransplation into mice (Wakimoto et al., 2012).
Upon exposure to serum, GSCs undergo transcriptional and
post-transcriptional reprogramming that leads to differentiation,
adhesion to substrate in vitro, and loss of tumor initiating capac-
ity in vivo (Suva` et al., 2014). Cells obtained from freshly dissoci-
ated human tumors were grown as spheroids under serum-free
conditions, with half of the culture being subsequently exposed
to serum to generate adherent progeny (Figure 1A). Spheroid-
derived cells from all three samples were highly tumorigenic in
immunocompromised mice, forming tumors that recapitulated
the histology of the original mass in vivo, whereas the adherentCell Reports 15, 1634–1647, May 24, 2016 1635
AB
D
E
F
G
C
Figure 1. GBM Sphere and Adherent Cell Properties
(A) Representative image of primary tumor cultures and their signature prop-
erties. Glioma stem-cell-like enriched spheroids (left) and adherent cells grown
as monolayers (right).
(B) Survival of mice injected with indicated numbers of sphere-derived and
adherent MGG8 cells (three mice per condition). Statistical significance was
calculated using log-rank test and is denoted as ****p% 0.0001.
(C) Representative histology of tumors formed by spheroid-derived cells.
(D) Hierarchical clustering of 20 miRNAs with highest fold change between
GSC and adherent states of MGG4, 8 and 11 cells, as measured by miRNA
microarrays. Color code indicates row Z score. Columns were reordered ac-
cording to distance and rows according to clusters of similar expression.
(E) Relative expression of mature let-7 family miRNAs as assessed by qPCR
and normalized to the respective adherent cell values. Data are presented as
the mean ± SD. p values are denoted as ***p% 0.001, **p% 0.01, *p% 0.05,
and ns (non-significant).
(F) WB of LIN28A and LIN28B in both cell states of all three primary GBM
cultures. A673 Ewing sarcoma cells and N-TERA2 embryonal carcinoma cells
were used as positive controls and GAPDH for equal loading assessment.
(G) Relative expression of a panel of validated let-7 target genes and SOX2
(a GSCsmarker) as assessed by qPCR, normalized to respective adherent cell
values. Data are presented as the mean ± SD. p values are denoted as ****p%
0.0001, ***p% 0.001, **p% 0.01, *p% 0.05, and ns (non-significant).
1636 Cell Reports 15, 1634–1647, May 24, 2016progeny failed to initiate tumor growth (Figures 1B and 1C; data
not shown). A fraction of spheroid-derived cells expressed
CD133 in vitro, a marker proposed to be associated with stem
cell features in GBM (Bao et al., 2006) (Figure S1A), whereas
adherent cells expressed markers of astrocytic and neuronal
differentiation (Figure S1B). Microarray-based analysis of miRNA
expression revealed that spheroids and adherent cells from
different tumors clustered according to the cell state (Figure
1D). Subsequent qPCR validation of spheroid and adherent
cell miRNA expression profiles confirmed robust upregulation
in spheroids of miRNAs reported to be highly expressed in
GSC-enriched CD133+ GBM cells (Schraivogel et al., 2011)
(Figure S1C).
Let-7 miRNA family members are repressed in embryonic
stem cells and CSCs, primarily because of LIN28-dependent
impairment of precursor maturation, which prevents let-7 target
transcript degradation. Intriguingly, our microarray data and cor-
responding qPCR validation not only failed to reveal global
repression of let-7 family miRNAs in GSCs compared to
adherent cells but also showed let-7 family members to be
among the most highly expressed miRNAs in both cell states
(Figure 1E; Figure S1D). Consistent with this observation, neither
LIN28A nor LIN28Bwas expressed in our GBMcells as assessed
by western blot (WB) (Figure 1F) and qPCR analysis (Figure S1E),
yet despite elevated let-7 expression, most validated let-7
targets were upregulated in GSCs compared to adherent cells
(Figure 1G). We therefore addressed the existence of a LIN28-in-
dependent mechanism that may contribute to inhibition of let-7
tumor- and stemness-suppressive functions in GBM.
Identification of the IMP2 Binding Repertoire in GBM
with PAR-CLIP
A possible explanation for the expression of both let-7 family
members and their target transcripts may lie in RBPs that oper-
ate through different mechanisms than that of LIN28. RBPs can
protect transcripts from miRNA-dependent degradation by
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Figure 2. PAR-CLIP of IMP2 in GBM Spheres and Adherent Cells
(A) Overview of the PAR-CLIP procedure. Cells that have taken up 4-SU are crosslinked by 365-nm irradiation and the protein of interest immunoprecipitated.
After SDS-PAGE, gel extraction, and proteinase K digestion of the protein-RNA complex, a library of bound RNAs is prepared and sequenced. Binding regions
(clusters) are identified using the sequencing coverage and T-to-C nucleotide transition introduced by reverse transcription at crosslinked sites.
(B) WB of IMP2 in three primary GBM cultures and MGG8 spheres sorted for CD133 expression with GAPDH as a loading control.
(C) Immunohistochemistry using anti-IMP2 antibody on normal brain and GBM sections.
(D) Percentage of IMP2 clusters in spheres (blue) and adherent cells (yellow) localizing to the indicated gene regions. HEK293T IMP2 clusters (Hafner et al., 2010)
and 10-fold randomization within genes are included for comparison.
(E) Overlap between genes bound by IMP2 in spheres, adherent cells, and HEK293T cells. The number of genes and fraction of the total are indicated within each
overlap.
(F) Distribution of total IMP2 binding coverage for gene quantiles separated according tomRNA expression (2,216 genes each) for spheroids. See also Figure S2K
for adherent cells.binding directly to MREs of target mRNAs. Thus, IMP1 and
IMP3 can counteract miRNA-mediated repression of MITF and
HMGA2 transcripts, respectively, by binding to their MREs (Gos-
wami et al., 2015; Jønson et al., 2014). Importantly, numerous
RBPs whose transcripts are themselves targets of a given
miRNA protect their own transcript in addition to the other target
mRNAs of the miRNA in question, thereby creating a positive
feedback loop (Xue et al., 2013). It has been shown that IMP2,
a validated let-7 target, is re-expressed in GBM and essential
for GSC maintenance and survival, in part through regulation of
GSC metabolism (Boyerinas et al., 2008; Janiszewska et al.,2012). Using TCGA glioblastoma database we found that IMP2
is co-expressed with several canonical let-7 target transcripts,
including HMGA1, HMGA2, IMP1, IMP3, and ARID3B (Fig-
ure S2A; data not shown). To address the putative role of IMP2
in miRNA target protection, we mapped its binding sites using
PAR-CLIP, a cross-linking method that takes advantage of the
incorporation of photoreactive ribonucleoside analogs into cells.
UV irradiation followed by immunoprecipitation of the RBP of
interest coupled to deep sequencing allows transcriptome-
wide identification of the binding sites (Figure 2A). In addi-
tion, T-to-C conversion in cDNAs at crosslinked nucleosidesCell Reports 15, 1634–1647, May 24, 2016 1637
delineate binding regions with high accuracy and allow their
discrimination from background RNA (Hafner et al., 2010).
IMP2 was expressed in both GSC-enriched spheroids and
their adherent progeny, but expression was markedly higher in
the former (Figure 2B). Accordingly, sphere-derived CD133+
cells displayed higher IMP2 expression than their CD133 coun-
terparts (Figure 2B; Figure S2B). IMP2 was undetectable in
normal adult brain sections (Figure 2C), marginally expressed
in normal human astrocytes, and strongly expressed in
GBM (Figure S2C). Interrogation of The Cancer Genome Atlas
(TCGA) database revealed robust IMP2 expression in all GBM
subtypes, with some minor variations (Figure S2D). Importantly,
depletion of IMP2 in GSCs by short hairpin RNA (shRNA)
strongly impaired their proliferation and self-renewal (Figures
S2E and S2F).
Two biological replicates of IMP2 PAR-CLIP were conducted
in both highly tumorigenic GSC-enriched spheroids and their
non-tumorigenic adherent progeny derived from the MGG8
primary tumor (Rheinbay et al., 2013), a GBM of the proneural
subtype where elevated expression of IMP2 has a negative
prognostic value (Janiszewska et al., 2012). RNA corresponding
to both IMP2 isoforms was pooled (Figure S2G), and we identi-
fied 167,278 and 70,451 binding regions (clusters) in both repli-
cates of spheres and adherent cells, respectively. The number
of binding sites per gene correlated well between the replicates
(Pearson spheres [Sph] 0.93, adherent [Adh] 0.86; Figure S2H).
Clusters preferentially located to 30 UTRs and protein-coding re-
gions (CDS) with differences between cell states (Figure 2D).
Within 30 UTRs and exons, the binding site distribution showed
no specific localization preference (Figure S2I). The majority of
non-30 UTR clusters occurred on transcripts that were co-bound
on the 30 UTR (Figure S2J). Assessment of the overlap of IMP2-
bound transcripts between HEK293T cells from an earlier study
(Hafner et al., 2010) and our GBM spheroid and adherent cell
cultures revealed numerous transcripts that were bound selec-
tively in one or the other cell state or in HEK293T cells (Fig-
ure 2E). By integrating RNA-sequencing data of both spheroids
and adherent cells, we found that IMP2 binding to transcripts
was highly dependent on their cell-state-associated basal
expression level, arguing against the possible influence of puta-
tive cell-state-dependent co-factors that may modulate IMP2
binding capability (Figure 2F; Figure S2K). Removal of genes
that were differentially expressed in GSCs, their adherent prog-
eny, and HEK293T cells markedly increased the proportion
of transcripts bound in common (Figure S2L). Locally, 30 UTR-
binding sites in all three cell types shared a substantial overlap
(25%–41%) in comparison to 10-fold randomization (2.7%–
4.5%) and IMP1 (14%) or IMP3 (13%) (obtained from Hafner
et al., 2010), with common sites having the highest mean
coverage (Figure S2M). The post-transcriptional network con-
trolled by IMP2 therefore varies significantly according to fac-
tors that determine mRNA expression levels, including the
cellular context itself. At a local level, the RNA-binding sites
display higher evolutionary conservation in both cell states
compared to a randomized background and flanking regions
(Figure S2N), and the 4-nt binding motif proposed by Hafner
et al. was strongly over-represented in our cluster sequences
(Figure S2O).1638 Cell Reports 15, 1634–1647, May 24, 2016IMP2 Binding Is Centered on Specific MicroRNA
Recognition Elements, Including let-7 Target Sites
Next, we selected 30 UTR-bound transcripts and analyzed the
corresponding IMP2 binding specificity. We observed that
IMP2 binds preferentially to 30 UTRs with high A+T nucleotide
content and MREs (Figure 3A; Figure S3A), both of which may
constitute moderate predictors of IMP2 UTR binding using a
general linear model with area under the curves (AUCs) of 0.77
and 0.75 in spheroid-forming and adherent cells, respectively
(Figure S3B). Within 30 UTRs, IMP2 bound directly to predicted
MREs of a large number of transcripts, suggesting that it may
contribute to miRNA-dependent transcript regulation. IMP2
binding to MREs was significantly higher than its binding to
random and flanking regions in GSCs, adherent cells, and
HEK293T cells (Figure 3B). Binding was particularly abundant
to MREs corresponding to tumor suppressor miRNAs and
miRNAs implicated in myogenesis, including miR-340, mir-143,
miR-186, miR-202, and miR-1 (Figure S3C), with MRE binding
coverage similar to that of let-7 targets (Figure S3D). Conversely,
MREs of miRNAs involved in neurogenesis and brain develop-
ment, including miR-9 (Figure S3D), miR-124, and miR-128,
displayed no significant enrichment in IMP2 binding density.
Together with a lack of correlation between miRNA expression
and binding, this hints at a binding mechanism that does
not implicate an obvious functional relationship with miRNAs
(Figures S3E and S3C). For validated let-7 targets, such as
HMGA2, we observed abundant IMP2 binding directly to spe-
cific MREs (Figure 3C).
Binding of IMP2 to MREs suggests a possible functional rela-
tionship with AGO2, the catalytic component of RISC. We there-
fore asked whether IMP2 and AGO2 reside in the same subcel-
lular compartments. Transcript degradation and turnover occur
in specific cellular compartments known as processing bodies
(P-bodies) (Parker and Sheth, 2007), which contain most of
the proteins involved in miRNA-mediated silencing, including
AGO2 (Sen and Blau, 2005). Confocal microscopy of adherent
GBM cells treated with antibodies against IMP2 and the
P-body marker EDC4 (Yu et al., 2005) revealed co-localization
of the two proteins, suggesting IMP2 interaction with RISC (Fig-
ure 3D). Co-localization of IMP2 and EDC4was observed in both
CD133+ and CD133 sphere fractions, suggesting that IMP2
localization to P-bodies is not cell-state dependent (Figure S3F).
Immunoprecipitation of IMP2 in RNase-free and RNase-treated
lysates from spheroids followed by WB analysis revealed RNA-
dependent association between AGO2 and IMP2 (Figure 3E),
which was also observed in both CD133+ and CD133 cells
(Figure S3G).
Modulation of IMP2 Levels Affects Target Gene
Expression in Primary GBM
To address the global functional relevance of IMP2 binding to
target transcripts and MREs, we conducted RNA sequencing
on MGG4 and MGG8 tumor-derived cells that had been sub-
jected to modulation of IMP2 expression. IMP2 was depleted
by shRNA in spheroids and expressed in adherent cells at levels
similar to those observed in native spheroids. Depletion of IMP2
in spheroids induced global downregulation of IMP2-bound
compared to IMP2 unbound transcripts (Figure 3F). Conversely,
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overexpression of IMP2 in adherent cells led to a general induc-
tion of bound transcripts, the most strongly induced being those
bound by IMP2 on MREs located in previously validated miRNA
targets (only targets ofmiRNAs expressed in GBMadherent cells
were considered) (Figure 3G). Importantly, the same observa-
tions applied when restricting transcript selection to let-7 targets
only (Figure 3H).
IMP2 Modulates miRNA-Dependent Target Silencing of
a Subset of let-7 Targets
Next, we explored the functional relevance of IMP2 binding to
let-7 MREs. First, we confirmed that IMP2-bound let-7 targets
identified by PAR-CLIP were significantly enriched in anti-IMP2
antibody RNA immunoprecipitates (RIPs) compared to isotype-
matched antibody counterparts in all three primary cultures (Fig-
ure S4A) and that IMP2 depletion and overexpression affected
both target mRNA and protein levels. qPCR analysis revealed
that expression levels of the let-7 and IMP2-bound targets
HMGA1, HMGA2, IMP3, and CCND1 were lowered in spheroids
depleted of IMP2 and increased in adherent cells overexpressing
IMP2 (Figures 4A and 4C). Western blots of IMP3, CCND1 and
HMGA2 confirmed these observations at the protein level (Fig-
ures 4B and 4D). Analysis of the same panel of targets by
qPCR andWBusing a different IMP2 shRNA yielded comparable
results, rendering off-target effects unlikely (Figure S4B). To
further verify the notion that IMP2 binding to MREs impairs
miRNA-dependent target silencing, we performed RIP on
AGO2 in IMP2-depleted and control spheroids (Figure 4E).
Upon IMP2 depletion, loading of several targets onto AGO2
increased, supporting miRNA-RISC as the effector pathway
for the observed changes in expression (Figure 4F). We
then assessed the effect of let-7 axis blockade on spheres
that were infected with a control vector or an shRNA target-
ing IMP2. Transfection of IMP2-depleted spheres with let-7
antagomiRs significantly rescued expression of the let-7 targets
IMP3, HMGA1, HMGA2, and CCND1 (Figure 4G; Figure S4C).
Finally, to validate the dependence of let-7-mediated target
gene silencing on IMP2 binding to let-7 MREs, we stably trans-Figure 3. Functional Relationship between IMP2 mRNA Binding and m
(A) CG and A+T content of IMP2 bound (blue) or non-bound (black) and MRE
represents a single 30 UTRwith densities of each group represented as lines and b
Figure S3A for adherent cells. Only non-overlapping 30 UTRs longer than 50 bp and
by Wilcoxon rank-sum test and is denoted as ****p% 0.0001.
(B) Sphere (blue), adherent (yellow), and HEK293T (gray; Hafner et al., 2010) cluste
Matched 103 randomized samples (dashed line) indicate clusters randomizedwith
let-7 and miR-9 MREs.
(C) UCSC genome browser view of theHMGA2 30 UTRwith TargetScan MRE pred
R2) are indicated. let-7 MREs are indicated in red.
(D) Immunofluorescence (IF) microscopy of IMP2 and EDC4 (P-bodymarker) expre
Pearson’s coefficient for co-localization is 0.602. See also Figure S3F for IF in sp
(E) Immunoprecipitation of endogenous IMP2 and rabbit control immunoglobulin
AGO2; Inp, input; FT, unbound fraction; IP, bound fraction. See also Figure S3G
(F and G) Cumulative plot of log2 fold changes of gene expression in response to
Gene subgroups are all transcripts (red); IMP2-bound transcripts that are targets
(dark green) of expressedmiRNAs; and IMP2 non-bound transcripts that are targe
determined by Kolmogorov-Smirnov test and is denoted as ****p% 0.0001, ***p
(H) Distribution of log2 fold changes in expression of all genes and let-7 target gen
in spheres (right) and IMP2 overexpression (OE) in adherent cells (right). Statist
as ****p% 0.0001.
1640 Cell Reports 15, 1634–1647, May 24, 2016fected MGG8 adherent cells with reporter constructs composed
of wild-type (WT) 30 UTRs of IMP3 and HMGA2 ligated to se-
quences encoding firefly luciferase. After selection, IMP2 or an
empty vector was stably introduced into these cells and lucif-
erase activity was measured 72 hr later. Introduction of IMP2
increased luciferase activity of both HMGA2 and IMP3 reporter
constructs compared to cells infected with the empty control
vector (Figure 4H). Mutation of the unique let-7 site in the IMP3
30 UTR and let-7 sites 2 and 3 (Figure 3C) in the HMGA2 30
UTR abolished the increase in luciferase activity observed
upon overexpression of IMP2 in cells expressing the WT 30
UTR reporters (Figure 4H), suggesting that IMP2 exerts its pro-
tective functions primarily through prevention of let-7-mediated
target gene silencing.
Expression of LIN28B Rescues the Effects of IMP2
Depletion in GSCs
If IMP2 provides an alternative pathway for let-7 target protec-
tion with respect to LIN28B, then introduction of LIN28B into
an IMP2-depleted background should rescue target transcript
levels. To test this possibility, we depleted IMP2 by shRNA in
MGG4 GSCs and 48 hr later expressed LIN28B using a lentiviral
system, verifying both IMP2 depletion and LIN28B expression by
WB (Figure 5A). LIN28B expression did not restore IMP2 (Fig-
ure 5A) but led to a robust decrease in mature let-7 levels,
whereas depletion of IMP2 alone did not significantly alter
mature let-7 expression (Figure 5B).
Expression levels of selected let-7 targets were then as-
sessed by qPCR in spheroids depleted of IMP2, expressing
LIN28B, or bearing a combination of LIN28B expression and
IMP2 depletion, compared to spheres expressing control vec-
tors. Introduction of LIN28B into spheres depleted of IMP2
restored HMGA1, HMGA2, CCND1, and IMP3 expression (Fig-
ure 5C), whereas the predicted let-7 target transcript BZW2,
which was unresponsive to IMP2 depletion, was also unrespon-
sive to LIN28B expression.
A major effect of IMP2 depletion in GSCs was reduced clono-
genicity, which was partially rescued by LIN28B expressioniRNAs
containing (red) or non-containing (dark red) 30 UTRs in spheres. Each point
oxplots. The number of 30 UTRs in each group is indicated in brackets. See also
the top 5%of clusters are considered. Statistical significancewas determined
r coverage in a 200-bp window centered on MREs with positive IMP2 binding.
in cluster-containing 30 UTRs. See Figure S3C formiRNA selection and S3D for
ictions. The coverage of replicate 1 (R1) and clusters of both replicates (R1 and
ssion inMGG8 adherent cells. Co-localization is shown in yellow (bottom right).
heres.
G in RNase-free and RNase A-treated conditions followed by WB for IMP2 and
for IP from lysates of spheres sorted for CD133 expression.
IMP2 depletion in spheres (F) and IMP2 overexpression in adherent cells (G).
(light green), experimentally validated targets (black, only G), and not targets
ts (blue) or not targets (violet) of expressedmiRNAs. Statistical significancewas
% 0.001, **p% 0.01, and ns (non-significant).
es between spheres and adherent cells (left), IMP2 depletion (knockdown [KD])
ical significance was determined by Wilcoxon rank-sum test and is denoted
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Figure 4. Effects of IMP2 Modulation on let-7 Target Gene Expression
(A) Relative expression of predicted IMP2-bound let-7 target genes upon IMP2 depletion inMGG4 andMGG8GSCs as assessed by qPCR. Data are presented as
the mean ± SEM of three experiments. p values are denoted as **p% 0.01, *p% 0.05, and ns (non-significant). See also Figure S4B for an alternative shRNA
targeting IMP2.
(B) WB of IMP2, IMP3, CCND1, and HMGA2 in MGG4 and MGG8 GSCs depleted (KD) or not of IMP2 using GAPDH as a loading control. See also Figure S4B for
an alternative shRNA targeting IMP2.
(C) Relative expression of predicted IMP-2-bound let-7 target genes upon overexpression (OE) of IMP2 inMGG4 andMGG8 adherent cells as assessed by qPCR.
The meanR SEM of three experiments is shown. p values are denoted as ****p% 0.0001, ***p% 0.001, **p% 0.01, *p% 0.05, and ns (non-significant).
(legend continued on next page)
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AC
D E F
B Figure 5. LIN28B-Mediated Rescue of the
Effects of IMP2 Depletion on GSC Clonoge-
nicity and Tumor Initiation
(A) WB of IMP2 and LIN28B in MGG4 spheroids
under control (left) or IMP2 KD (right) conditions,
each transfected with an empty vector or ex-
pressing LIN28B. GAPDH provided a loading
control.
(B) Relative expression of mature let-7 family
members in MGG4 GSCs upon depletion of IMP2
alone or in combination with LIN28B expression,
normalized to non-silencing (NS) and empty vector
conditions. miR-9, whose maturation is LIN28 in-
dependent, is provided as a control. Data are
presented as the mean ± SEM of two experiments.
p values are denoted as **p% 0.01, *p% 0.05, and
ns (non-significant).
(C) Relative expression of putative let-7 target
genes in response to IMP2 depletion, LIN28B
expression, or a combination of both normalized to
non-silencing (NS) and empty vector controls in
MGG4 GSCs. HES1 is a validated miR-9 target not
bound by IMP2 inGSCs used as a control. Data are
presented as the mean ± SEM of two experiments.
p values are denoted as ****p % 0.0001, ***p %
0.001, **p % 0.01, *p % 0.05, and ns (non-sig-
nificant).
(D) Clonogenic assay of MGG4 GSCs bearing
control vectors (empty and non-silencing, NS,
vectors), LIN28B expression, IMP2 KD and a
combination of LIN28B expression and IMP2 KD.
The mean ± SEM of three independent experi-
ments is shown. ns, non-significant, **p % 0.01,
and ****p% 0.0001.
(E) Survival curve of mice injected with 10,000
MGG4 GSCs expressing control vectors, LIN28B,
IMP2 shRNA (KD) or a combination of LIN28B and
IMP2 KD. Statistical significance was calculated
using log-rank test and is denoted as **p % 0.01
and ns (non-significant) (five mice per group).
(F) Log2 expression levels of IMP2 and LIN28A/B
according to the 166 TCGA HiSeq v2 GBM data-
set. The 20% highest and lowest expressed genes
are included for comparison.(Figure 5D). To extend our observations in vivo, we injected five
mice each orthotopically with 10,000 MGG4 spheres expressing
control non-silencing vectors, depleted of IMP2, expressing
LIN28, or bearing a combination of IMP2 depletion and LIN28B
expression. Between 56 and 81 days following injection,
all mice that had received cells expressing control vectors,
LIN28B, and LIN28B combined with IMP2 depletion succumbed
to tumors, whereas mice bearing cells depleted of IMP2 alone(D) WB of IMP2, IMP3, CCND1, and HMGA2 in MGG4 and MGG8 adherent cells
control.
(E) WB of input and 10% AGO2 RIP in control and IMP2 KD conditions in MGG4
(F) Transcript levels in control and IMP2 KD cells in input and AGO2 RIP fractio
respective non-silencing control. p values are denoted as **p% 0.01, *p% 0.05
(G) Relative expression of predicted IMP2-bound let-7 targets upon IMP2 depletio
SOX10, which is not a let-7 target but is IMP2 bound, is used as a control. Bars rep
cells. p values are denoted as **p% 0.01, *p% 0.05, and ns (non-significant).
(H) Reporter assays for wild-type (wt) and let-7 binding site mutated (mut.) HMGA
luciferase reporter vectors and expressing either an empty vector or IMP2. Lucifer
vector. Bars represent mean ± SD. ns, non-significant, ***p% 0.001, and ****p%
1642 Cell Reports 15, 1634–1647, May 24, 2016manifested no signs of tumor growth (Figure 5E). All of the tu-
mors displayed typical GBM histology with robust angiogenesis,
extensive necrosis, and a high degree of invasiveness (data not
shown). Importantly, the rate of tumor development from control,
LIN28B-expressing, and IMP2-depleted/LIN28B-rescued cells
was comparable.
TCGA database interrogation of primary GBM tumor bulk
samples indicates that the expression of both LIN28A andoverexpressing IMP2 or containing empty vector using GAPDH as a loading
GSCs as a control for the immunoprecipitated quantity.
ns. Levels of input in IMP2 KD and AGO2 RIP fractions are normalized to the
, and ns (non-significant).
n and/or treatment with let-7 antagomiRs as assessed by qPCR inMGG8 cells.
resent the mean ± SD. See also Figure S4C for the same experiment onMGG4
2 and IMP3 30 UTRs performed in MGG8 adherent cells stably transfected with
ase activity was normalized to total protein content and transfection with empty
0.0001.
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Figure 6. IMP2 in Neural Stem Cells
(A) Relative expression of IMP2 in mouse embryo (E14.5 [ED14.5]) and P21 and
P50 brains as assessed by qPCR normalized to E14.5. Data are presented as
the mean ± SEM of three experiments. p values are denoted as ***p% 0.001,
**p% 0.01, and *p% 0.05.
(B) Relative expression of IMP2 in NSCconditional Imp2KOanimals (Imp2fl/fl3
NestinCre) as assessedbyqPCR, normalized toWTanimals (Imp2fl/fl). Data are
presented as the mean ± SEM of two experiments. p values are denoted as
**p% 0.01 and *p% 0.05.
(C) Clonogenic assay of WT and Imp2 KO NSCs derived from E14.5 and P21
mouse brains, normalized to WT cells. Data are presented as the mean ± SEM
of three independent experiments. ***p% 0.001 and *p% 0.05.
(D) Percentage of positive cells for GFAP (astrocytic marker) and BIII-tubulin
(neuronal marker) as assessed by immunofluorescence microscopy. Bars
represent the mean ± SD. p values are denoted as ***p% 0.001 and *p% 0.05.
(E) Cumulative plot of log2 fold changes of gene expression in response to
Imp2 knockout in E14.5 and P21 brains. Gene subgroups are all transcripts
(red), transcripts with no IMP2 binding in human and mouse let-7 targets
(light green), no IMP2 binding in human and targets of any miRNA (blue),
IMP2 binding in human and mouse let-7 targets (violet), and IMP2 binding in
human and targets of any miRNA (green). Statistical significance wasLIN28B is marginal compared to IMP2 (Figure 5F). Although we
cannot formally exclude the possibility that a small fraction of
cells display higher expression of LIN28A/B, these observations
argue against significant expression of LIN28 in primary GBM tu-
mors, consistent with the status of the primary cells used in this
study.
IMP2 Expression in Neural Stem Cells
IMP2 is highly expressed in the developing brain with a peak
around mid-gestation in mice (Nielsen et al., 1999) and its deple-
tion in NSCs favors astrocytic lineage commitment (Fujii et al.,
2013). Normal stem cells share some of their properties with
CSCs and are believed to be candidate cells of origin of various
malignancies (Visvader, 2011). We therefore addressed possible
similarities between GSCs and NSCs with respect to IMP2-
dependent control of let-7 target gene silencing.
We examined Imp2 expression in brains extracted from Imp2
floxed (Imp2fl/fl) embryos and mice at different stages of devel-
opment (embryonic day 14.5 [E14.5], postnatal day 21 [P21],
and P50). Consistent with previous work, Imp2 expression was
highest during embryonic development (Nielsen et al., 1999;
Nishino et al., 2013), with a gradual decrease following birth (Fig-
ure 6A). Immunohistochemical staining of brain sections re-
vealed strong IMP2 expression at E14.5, detectable expression
at P21, and marginal expression at P50 (data not shown). To
delete Imp2 in NSCs, we crossed Imp2fl/fl mice with a strain ex-
pressing Cre recombinase under the control of the nestin pro-
moter (Dubois et al., 2006). We then derived NSCs from Imp2fl/fl
mice (WT) and Imp2fl/fl Nestin Cre animals (knockout [KO]) of
E14.5 and P21 for further analysis. qPCR analysis confirmed
Imp2 suppression in KO-mice-derived NSCs compared to con-
trols (Figure 6B). Similar to its effect in GSCs, Imp2 depletion
impaired NSC clonogenicity, and more strongly so in P21
mice, when Imp1 and Imp3 are no longer expressed (Figures
6A and 6C).
Let-7 and its targets are key regulators of NSC maintenance
and differentiation (Nishino et al., 2008; Yu et al., 2015) and,
along with let-7 target sites, are highly conserved during evolu-
tion and across species (Pasquinelli et al., 2000). In addition to
their actions during development, let-7 family members are
required for differentiation of glial progenitor cells to astrocytes
(Shenoy et al., 2015). Consistent with previous reports using
shRNAs targeting Imp2 in NSCs, Imp2 KO NSCs displayed
increased astrocytic and reduced neuronal differentiation (Fig-
ure 6D). Whether this phenotype is the result of modulation of
the let-7 axis, which is itself involved in the control of differentia-
tion of neural progenitor cells, remains to be addressed. To
determine whether IMP2 has a similarly conserved role toward
let-7 target transcripts in NSCs, we sequenced NSC RNA (after
7 days of NSC culture in vitro) derived from WT and KO
E14.5 embryos and P21 mice. We made the assumption thatdetermined by Kolmogorov-Smirnov test and is denoted as ****p % 0.0001
and **p % 0.01.
(F) Relative expression of putative IMP2-bound validated let-7 target genes
upon depletion of IMP2 in NSCs as assessed by qPCR normalized toWT. Data
are presented as themean ±SEM of two experiments. p values are denoted as
**p% 0.01, *p% 0.05, and ns (non-significant).
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IMP2-bound transcripts are conserved between GSCs and
NSCs and analyzed the effect of IMP2 depletion on putatively
bound transcripts in NSCs. Consistent with our observations
in GSCs, let-7 target transcript levels were lower in Imp2 KO
NSCs than in controls, supporting a protective role for IMP2 (Fig-
ure 6E). Validation by qPCR of the RNA-sequencing data for
the let-7 targets Ccnd1, Peg10, Hmga1, Hmga2, and Imp3
confirmed these results (Figure 6F).
DISCUSSION
Comparison of miRNA expression profiles of GSCs and
their non-tumorigenic progeny from three independent primary
GBMs revealed differential expression of a subset of miRNAs be-
tween the two cell states but comparable and elevated expres-
sion of mature tumor and stemness suppressive let-7 family
members. Consistent with these findings, the let-7 maturation
repressors LIN28A and LIN28B, which are re-expressed in
15% of predominantly undifferentiated malignant tumors as
well as in CSCs of diverse cancer types (Nguyen et al., 2014; Vis-
wanathan et al., 2009), were undetectable. Expression of let-7
target genes in GSCs in the face of intact let-7 maturation there-
fore argued for an alternative mechanism that impairs the ability
of let-7 family members to induce target gene silencing. Preven-
tion ofmiRNA-mediated gene silencing by RBPs that bind to or in
close proximity to MREs on target mRNAs provided a readily
testable alternative. An elegant study reported this to be the
mechanismwhereby the RBP PTB, a target of miR-124, can pro-
tect its bound transcripts, including its own, from the action of
miR-124 (Xue et al., 2013). We previously showed that the RBP
IMP2, which contains two let-7 MREs in its 30 UTR, is highly ex-
pressed in GSCs and essential for their maintenance and tumor
initiating capacity (Janiszewska et al., 2012). Co-expression of
IMP2 and several validated let-7 targets in GSCs, as revealed
by TCGA expression analysis, supports a functional relationship
between IMP2 and let-7 analogous to that between PTB and
miR-124, which our observations strongly favor.
PAR-CLIP, applied to a primary proneural GBM grown as
a GSC-enriched spheroid culture and its non-tumorigenic
adherent progeny, identified the mRNA repertoire bound to
IMP2 on a transcriptome-wide scale. Analysis of IMP2 binding
to mRNA revealed that IMP2 preferentially localizes to 30 UTRs
with high AT content and MREs and, more importantly, showed
that its binding density is enriched on a subset of MREs,
including let-7 target sites, suggesting that IMP2 protects these
transcripts frommiRNA-mediated silencing. Consistent with this
notion, we found that transcripts bound by IMP2 onMREs of pre-
viously validated miRNA targets constitute the most strongly
suppressed class of mRNAs upon IMP2 depletion. Thus, protec-
tion from RISC/AGO-mediated silencing by IMP2 explains the
observed expression of both let-7 family miRNAs and their target
genes. Accordingly, depletion of IMP2 led to decreased expres-
sion of the let-7 target gene repertoire, which includes genes
implicated in oncogenesis and maintenance of stemness. As
IMP2 is highly expressed in all GBM molecular subtypes, its
functional role is most likely similar irrespective of subclass.
IMP2 protection is not limited to let-7 target genes. Consistent
with this notion, PAR-CLIP revealed increased binding density of1644 Cell Reports 15, 1634–1647, May 24, 2016IMP2 on MREs targeted by miRNAs that were not expressed in
GBM. Although let-7 target genes displayed the highest fold
changes in response to IMP2 depletion and overexpression,
IMP2-bound targets of other expressed miRNAs responded in
a similar fashion. Ultimately, the effect of IMP2 on target tran-
scripts most likely varies according to the cell-context-depen-
dent repertoire of mRNAs, miRNAs, and RBPs.
Comparison of our data to previously published PAR-CLIP
studies of IMP1-3 in HEK293T cells revealed strong overlap of
their binding sites, including let-7 MREs. Furthermore, a recent
study suggested that IMP3 is co-expressed with HMGA2 in a
broad range of solid tumors and revealed that IMP3 has the abil-
ity to safeguard the HMGA2 transcript from let-7 degradation
(Jønson et al., 2014), suggesting functional redundancy between
IMP2 and IMP3 for at least a subset of transcripts. To what
degree IMP3 may participate in IMP2-dependent protection of
let-7 target genes in GSCs remains to be determined. However,
it is conceivable that IMP3 expression provides a fail-safe mech-
anism to ensure preservation of key let-7 target genes required
for GSC maintenance. Unlike IMP3, IMP2 co-localized with
P-bodies and co-immunoprecipitated with AGO2 in an RNA-
dependent fashion, suggesting that IMP2 and AGO2 are not
located in separate cellular compartments, as IMP3 and AGO2
appear to be (Jønson et al., 2014). Thus, despite putative partial
functional redundancy, IMP2 and IMP3 may employ distinct
effector pathways.
Suppression of let-7 target gene expression upon IMP2 deple-
tion was accompanied by loss of GSC clonogenicity and tumor
initiating capacity. Overexpression of IMP2, on the other hand,
did not alter the GSC phenotype, suggesting that the maximal
effect of IMP2 on clonogenicity and tumor initiation had been
reached within the physiological expression level in GSCs. The
ability of LIN28B to rescue the IMP2 depletion phenotype
without restoring IMP2 expression reflects the distinct mecha-
nisms that LIN28 and IMP2 employ to maintain let-7 target
gene expression. The high selectivity of LIN28 for inhibition of
let-7 biogenesis argues that the observed phenotypic rescue is
primarily due to restoration of let-7 and not some unrelated
miRNA target gene expression. However, the participation of
putative let-7-independent mechanisms cannot be formally
excluded. In addition to regulating let-7 target gene expression,
albeit by different mechanisms, IMP2 and LIN28 share a broad
range of intriguing functional similarities. They include a tempo-
rally and spatially overlapping expression pattern during normal
development (Balzer et al., 2010; Christiansen et al., 2009), the
ability to enhance translation of IGF-2 (Polesskaya et al., 2007;
Dai et al., 2011), behavior as bona fide let-7 targets, the ability
to block glial differentiation (Fujii et al., 2013; Balzer et al.,
2010), and implication in cellular bioenergetics. LIN28 is impli-
cated in the regulation of glucose metabolism (Zhu et al., 2011)
and in coordinating growth through let-7-dependent regulation
of numerous metabolic genes. (Zhu et al., 2011; Shyh-Chang
and Daley, 2013). LIN28 can also enhance oxidative phos-
phorylation (OXPHOS) during wound healing through let-7-inde-
pendent mechanisms, and inhibition of OXPHOS reduces its
ability to promote tissue repair (Shyh-Chang et al., 2013). Simi-
larly, IMP2 regulates metabolism by promoting OXPHOS in
GSCs, in part through physical interactions with mitochondria
(Janiszewska et al., 2012).Whether or not let-7 blockade is impli-
cated in this particular function of IMP2 remains to be deter-
mined, but regulation of GSC bioenergetics may constitute a
mechanism that contributes to both IMP2 and LIN28-mediated
CSC maintenance.
IMP2 implication in GSCmaintenance reflects its physiological
role in NSC development. In NSCs, IMP2 is expressed well after
IMP1 and IMP3 repression has occurred and protects let-7 target
transcripts, reminiscentof the situation inGSCs. IMP2depletion in
NSCs led to global downregulation of putatively bound let-7 tar-
gets, which were similarly repressed in IMP2-depleted GSCs,
and reduced clonogenicity, indicating conserved function be-
tween normally developing cells and GSCs.
Taken together, we have shown that the RBP IMP2 protects
let-7 miRNA family target genes from silencing and promotes
GSC clonogenicity and tumor-initiating capacity. As such, it pro-
vides an important alternative mechanism for CSC maintenance
to LIN28-dependent inhibition of let-7 biogenesis. Therapeutic
targeting of IMP2-dependent let-7 target gene protection may
provide an attractive option toward abolishing cellular hierarchy
in GBM, which, if effective, could lead to major improvement in
the prognosis of one of the deadliest human malignancies.
EXPERIMENTAL PROCEDURES
Cell Culture
GSCs used were characterized in previous studies (Wakimoto et al., 2012;
Rheinbay et al., 2013; Suva` et al., 2014). GSCs were grown in Neurobasal me-
dium (Invitrogen) supplemented with L-glutamine (GIBCO), B27, N2 (Invitro-
gen), and recombinant hEGF and hFGF2 (R&D Systems). GSCs differentiation
was induced by adding 10% fetal calf serum (FCS) and removing growth fac-
tors for 7 days on plates coated with 100 mg/ml poly-D-lysine and 15 mg/ml
laminin (Sigma-Aldrich). For further details, see Supplemental Experimental
Procedures.
Clonogenic Assays
GSCs infected with non-silencing or IMP2 pGIPZ shRNA (RHS4346 and
V3LHS-393362, Dharmacon) were mechanically dissociated and plated at
single-cell density in 96-well low-adherence plates. Sphere numbers were
assessed after 2 weeks by imaging and statistical significancewas determined
with Student’s t test using GraphPad Prism 6 software.
Lentiviral Infections and Transfections
Lentiviruses produced in HEK293T transfected with the plasmid of interest,
GAG/POL, and VSV using FuGene HD (Promega) were used to infect GBM
cells. Cells were infected for 16 hr and selected in 2 mg/ml puromycin for
4 days. V3LHS-393362 for IMP2 depletion (IMP2 sh-1) and a scrambled
shRNA (Dharmacon) were used. The targeting sequence and vector corre-
sponding to IMP2 sh-2 were described previously (Janiszewska et al., 2012).
For let-7 miRNA blockade, pooled scrambled or let-7 antagomiRs (Exiqon)
were transfected into GBM cells with RNAiMAX (Thermo Fischer Scientific)
and the cells were harvested 48 hr later. For further details, see the Supple-
mental Experimental Procedures.
RNA Extraction, cDNA Synthesis, and qPCR
RNAwas extracted using miRCURY (Exiqon) with DNase treatment (QIAGEN).
500 ng RNA was reverse transcribed using M-MLV (Promega). qPCR was per-
formed with TaqMan Universal PCR (Applied Biosystems) or Power SYBR
green (Applied Biosystems). Each qPCR reaction was performed in triplicate
and normalized to PPIA and 18S (Thermo Fisher Scientific). For miRNA-qRT-
PCR, 50 ng template RNA was reverse transcribed with a universal cDNA syn-
thesis kit (Exiqon). qPCRwas done in triplicatewith primers formaturemiRNAs
(microRNA LNA PCR primer sets, Exiqon) normalized to RNU5G andSNORD49a (Exiqon). Statistical significance was determined using Student’s
t test. For further details and primers used, see the Supplemental Experimental
Procedures.
PAR-CLIP
PAR-CLIP was performed according to Hafner et al. (2010), with minor modi-
fications. For GSC-enriched spheroids,108 dissociated cells were incubated
overnight with 100 mM 4SU (Sigma-Aldrich) and crosslinked with 0.36 J/cm2
total 365-nm irradiation. For adherent GBM cells, 33 108 subconfluent cells
were crosslinked with 0.15 J/cm2 total 365-nm irradiation. Before clearing,
both cell lysateswere treatedwith RNase T1 and RNase-free DNase I (Fermen-
tas) and sonicated. Immunoprecipitation was performed with 20 mg anti-IMP2
(MBL) antibody for 3 hr. For further details and antibodies used, see the Sup-
plemental Experimental Procedures.
Sequence Alignment and Computational Analysis
Sequenced PAR-CLIP reads were adaptor-trimmed with a custom script and
aligned to the hg19 human genome using Bowtie 0.12.9 (Langmead et al.,
2009). Cluster identification was done with wavClusteR 2.2.0 (Comoglio
et al., 2015). RNA-sequencing reads were aligned to the hg19 human genome
build using TopHat 2.0.12 (Trapnell et al., 2009). Differential expression anal-
ysis was done in R 3.2.0 using edgeR 3.10.2 (Robinson et al., 2010). Further
analysis was performed with custom scripts based on Bioconductor functions
(Huber et al., 2015), and the results are available upon request. See also the
Supplemental Experimental Procedures.
RNA Immunoprecipitation, Co-immunoprecipitation of IMP2, and
Western Blots
RIP assay kit for microRNA (MBL International) was used according to the
manufacturer’s recommendations. 5% input and 40 mg protein lysates from
2 3 107 cells were used for RNA extraction and WB, respectively. Immuno-
precipitation with anti-AGO2 and isotype-matched antibodies was performed
with 5 mg pre-cleared lysates at 4C for 2 hr. 10% of final beads were used
for WB and 90% for RNA extraction. 100 ng input and RIP RNA was reverse
transcribed and analyzed by qPCR. Enrichment of targets was calculated us-
ing ddCT (Livak and Schmittgen, 2001). For further details and antibodies
used, see the Supplemental Experimental Procedures.
Immunofluorescence
Immunofluorescence (IF) was performed as described previously (Janiszew-
ska et al., 2012) using a Leica SP5AOBS confocal microscope at the Imaging
Core Facility of the University of Lausanne. Co-localization was calculated us-
ing ImageJ (ImageJ, Rasband, W.S., NIH). For additional details, see the Sup-
plemental Experimental Procedures.
Neural Stem Cell Extraction and Culture
Extraction of NSCs frommouse brains was performed as described previously
(Azari et al., 2010, 2011). NSCs were cultured in NeuroCult NSC Basal Medium
with 10% NeuroCult Proliferation Supplement (STEMCELL Technologies) and
20 ng/ml EGF. For post-natal-derived NSCs, 10 ng/ml FGF2 and 2 mg/ml
heparin were added. Neurospheres were grown for 6–8 days in ultra-low-
adherence flasks (Corning Life Sciences) and passaged every 4–7 days using
Accutase (STEMCELL Technologies). Differentiation capacity was assessed
by adding 10% NeuroCult Differentiation Supplement (STEMCELL Technolo-
gies) to the medium for 10 days followed by IF analysis using anti-GFAP (astro-
cytic) and anti-Tuj-1 (neuronal) antibodies.
Mouse Strains and Genotyping
Imp2 floxed mice were a gift of Prof. Bernard Thorens (University of Lausanne)
produced by Genoway (C57BL6 background). CNS knockouts were gener-
ated by breeding Imp2 floxed with Nestin-cre mice (C57BL6 background)
obtained from the Transgenic Core Facility of Ecole Polytechnique Fe´de´ral
de Lausanne. The recombination profile has been described previously (Du-
bois et al., 2006). Experiments were performed under license number
VD2488 (approved by the Service de la Consommation et des Affaires Ve´te´r-
inaires, Epalinges, Switzerland). All mice were genotyped and knockout effi-
ciencies tested. See also Supplemental Experimental Procedures.Cell Reports 15, 1634–1647, May 24, 2016 1645
miRNA Array
Probe intensities provided by the facility were analyzed using limma. Log-
transformed values were normalized between arrays using cyclic-loess. For
hierarchical clustering, the 20 miRNAs with highest fold changes were clus-
tered by complete linkage using base R (3.2.0) functions.
Luciferase Assays and 30 UTR Site-Directed Mutagenesis
The 30 UTRs of HMGA2 and IMP3 were cloned into a lentiviral reporter
vector (Lenti-reporter-Luc Vector, ABMgood). Cytosine bases in let-7
MREs were mutated to guanine using a QuickChange II XL site-directed
mutagenesis kit (Agilent Technologies) according to the manufacturer’s
recommendations. MGG adherent cells were infected with reporter
vectors and selected with puromycin. 72 hr after IMP2 or control transfec-
tion, samples were processed with a luciferase assay system (Promega)
and measured on a SynergyMX instrument (BioTek Instruments). Lucif-
erase activity was normalized to total protein content and statistical
significance calculated using Student’s t test with GraphPad Prism 6
software.
Xenografts of Glioma Stem Cells
Intracranial xenografts were performed as previously described (Suva` et al.,
2014). Experiments were performed under license number VD2852 (approved
by the Service de la Consommation et des Affaires Ve´te´rinaires, Epalinges,
Switzerland). Statistical significance was determined using log-rank test with
GraphPad Prism 6 software.
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